News
CaReMe CKD Study published in Lancet Regional Health Europe
Tiago Taveira-Gomes, CEO and Clinical Head of Sigil Scientific Enterprises, our partner for Real World Evidence (RWE) studies, contributed as author for a study across several European countries published by The Lancet.
Tiago said: "I am extremely grateful and humbled for having had the opportunity to participate in the CaReMe CKD Study published in Lancet Regional Health Europe last week. I hope our findings can be used to determine the potential impact and cost savings from interventions targeting CKD patients."
To learn more about this study, please visit: Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study - The Lancet Regional Health – Europe
